Bone metastasis

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

Retrieved on: 
Martedì, Febbraio 2, 2021
Clinical medicine, Cancer, Medicine, Cancer treatments, Oncology, Anatomical pathology, Sarcoma, Chemotherapy, Lung cancer, Doxorubicin, Epithelioid sarcoma, Bone metastasis

While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.

Key Points: 
  • While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.
  • While 10% to 30% of patients with sarcoma lung metastases may initially respond to doxorubicin, most will relapse leaving the majority of these patients without an alternative chemotherapy.
  • "Our ongoing sponsored research continues to expand the potential uses for Annamycin," commented Walter Klemp, Chairman and CEO of Moleculin.
  • "We expect that one, and potentially two, clinical trials in sarcoma lung metastases should be up and running this year."

Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns

Retrieved on: 
Venerdì, Novembre 20, 2020
Musculoskeletal system, Physical sciences, Anatomy, Strontium-89, Bone metastasis, Bone, Strontium, Radiation therapy, Metástasis, Metastatic breast cancer

Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.

Key Points: 
  • Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.
  • "Q BioMed is committed to making Strontium89, an effective treatment for pain resulting from bone metastases, widely available again.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns

Retrieved on: 
Venerdì, Novembre 20, 2020
Musculoskeletal system, Physical sciences, Anatomy, Strontium-89, Bone metastasis, Bone, Strontium, Radiation therapy, Metástasis, Metastatic breast cancer

Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.

Key Points: 
  • Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.
  • "Q BioMed is committed to making Strontium89, an effective treatment for pain resulting from bone metastases, widely available again.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma

Retrieved on: 
Venerdì, Novembre 20, 2020
Other Health, Research, General Health, Radiology, Pharmaceutical, Oncology, Clinical trials, Science, Surgery, Biotechnology, Other Science, Health, Organ systems, Skeletal disorders, Denosumab, Bone metastasis, Multiple myeloma, Medication-related osteonecrosis of the jaw, Amgen, Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors and in Patients with Multiple Myeloma, XGEVA® (denosumab), BeiGene

The most common adverse reactions in patients receiving XGEVA with bone metastasis from solid tumors were fatigue/asthenia, hypophosphatemia, and nausea.

Key Points: 
  • The most common adverse reactions in patients receiving XGEVA with bone metastasis from solid tumors were fatigue/asthenia, hypophosphatemia, and nausea.
  • We congratulate our teams and celebrate the approval of this new indication of XGEVA for the prevention of skeletal-related events.
  • XGEVA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  • XGEVA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.

Roswell Park Experts Ask: What Drives Painful Bone Metastasis in Prostate Cancer, and Can it Be Prevented?

Retrieved on: 
Mercoledì, Novembre 18, 2020
Anatomy, Branches of biology, Musculoskeletal system, Infectious causes of cancer, Histopathology, Prostate cancer, Bone metastasis, Cancer, Metástasis, Prostate, Tumor microenvironment, Bone

Prostate tumors can metastasize to a number of different organs, including the liver, lymph nodes and bone.

Key Points: 
  • Prostate tumors can metastasize to a number of different organs, including the liver, lymph nodes and bone.
  • People with advanced prostate cancer often develop bone metastases lesions of prostate cancer growing on distant bones that are very painful and difficult to treat.
  • Given the significant differences between the microenvironments surrounding the bone and prostate, a team from Roswell Park Comprehensive Cancer Center set out to learn more about how prostate tumors survive and grow in the bone.
  • The Roswell Park research team discovered that prostate tumors are able to alter their metabolism and produce additional fats by stimulating this enzyme.

Tumor Ablation Market Worth $ 1072.87 Million, Globally, by 2027 at 12.1% CAGR: Verified Market Research

Retrieved on: 
Giovedì, Novembre 5, 2020
Medical specialties, Medicine, Clinical medicine, Interventional radiology, Microwave ablation, Cryoablation, Ablation, Bone metastasis, Liver cancer, Radiofrequency ablation, Combinatorial ablation and immunotherapy

JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".

Key Points: 
  • JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".
  • According to Verified Market Research, the Global Tumor Ablation Market was valued at USD 458.30 Million in 2019 and is projected to reach USD 1072.87 Million by 2027, growing at a CAGR of 12.1% from 2020 to 2027.
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market.
  • Verified Market Research has segmented the Global Tumor Ablation Market on the basis of Technology, Mode of Treatment, Application and Geography.

Tumor Ablation Market Worth $ 1072.87 Million, Globally, by 2027 at 12.1% CAGR: Verified Market Research

Retrieved on: 
Giovedì, Novembre 5, 2020
Interventional radiology, Medicine, Clinical medicine, Medical specialties, Microwave ablation, Cryoablation, Ablation, Bone metastasis, Cancer, Radiofrequency ablation

Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market

Key Points: 
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market
    JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".
  • According to Verified Market Research, the Global Tumor Ablation Market was valued at USD 458.30 Million in 2019 and is projected to reach USD 1072.87 Million by 2027, growing at a CAGR of 12.1% from 2020 to 2027.
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market.
  • Verified Market Research has segmented the Global Tumor Ablation Market on the basis of Technology, Mode of Treatment, Application and Geography.

EANM 2020: ITM Emphasizes Commitment to Developing Targeted Radionuclide Therapies With Satellite Symposium on Bone Metastases

Retrieved on: 
Giovedì, Novembre 5, 2020
Finance, Genetics, Clinical trials, Professional services, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, Musculoskeletal system, Anatomy, Organ systems, Histopathology, Bone metastasis, Prostate cancer, Cancer, Medication-related osteonecrosis of the jaw, Bone, Targeted therapy, Management of prostate cancer, Metastatic breast cancer

Professor Sartor focused on the current and future management paradigms of metastatic bone disease in castrate-resistant prostate cancer.

Key Points: 
  • Professor Sartor focused on the current and future management paradigms of metastatic bone disease in castrate-resistant prostate cancer.
  • This topic is particularly relevant as about 90 percent of patients suffering from this disease develop bone metastases.
  • These bone targeted therapies have the potential to complement other cancer treatment modalities, e.g.
  • It created a platform for interactive discussions on novel concepts and clinical approaches to the management of patients with metastatic bone disease.

Profound Medical to Release Second Quarter 2020 Financial Results on August 6 – Conference Call to Follow

Retrieved on: 
Mercoledì, Luglio 22, 2020
Neoplasms, Medicine, Clinical medicine, Gynaecological neoplasia, RTT, Uterine fibroid, Sonalleve MR-HIFU, Bone metastasis, Interventional radiology, High-intensity focused ultrasound

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
  • Sonallevehas also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

BetterLife (OTCQB:BETRD) Launches Website Emphasizing 3 Potentially Ground Breaking Treatments

Retrieved on: 
Martedì, Luglio 14, 2020
Musculoskeletal system, Organ systems, Skeletal system, Osteonecrosis, Bone metastasis, Bone, Medication related osteonecrosis of the jaw, Metástasis, Metastatic breast cancer, RANKL

The new website, http://www.blifetherapeutics.com , provides visitors with an overview of the Companys treatment development pipeline, including information on the trial Phases for each of the treatments.

Key Points: 
  • The new website, http://www.blifetherapeutics.com , provides visitors with an overview of the Companys treatment development pipeline, including information on the trial Phases for each of the treatments.
  • Not only did IFNa2b help patients' immune systems clear thecoronavirusfaster, it also seemed to reduce certain inflammatory proteins linked to severe COVID-19 complications.
  • AP-002 is unique in that it has both anti-bone resorption and direct anti-tumour cell killing activity.
  • Bone metastases often result in severe pain, spinal cord compression and cancer-induced bone fractures, collectively referred to as skeletal related events (SREs).